NO975520D0 - Behandling av T-celle-medierte autoimmune forstyrrelser - Google Patents

Behandling av T-celle-medierte autoimmune forstyrrelser

Info

Publication number
NO975520D0
NO975520D0 NO975520A NO975520A NO975520D0 NO 975520 D0 NO975520 D0 NO 975520D0 NO 975520 A NO975520 A NO 975520A NO 975520 A NO975520 A NO 975520A NO 975520 D0 NO975520 D0 NO 975520D0
Authority
NO
Norway
Prior art keywords
treatment
cell mediated
mediated autoimmune
autoimmune disorders
antagonist
Prior art date
Application number
NO975520A
Other languages
English (en)
Other versions
NO322391B1 (no
NO975520L (no
Inventor
Randolph J Noelle
Eric Claassen
Original Assignee
Dartmouth College
Nl Organisatie Vor Toegepastna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College, Nl Organisatie Vor Toegepastna filed Critical Dartmouth College
Publication of NO975520D0 publication Critical patent/NO975520D0/no
Publication of NO975520L publication Critical patent/NO975520L/no
Publication of NO322391B1 publication Critical patent/NO322391B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO19975520A 1995-06-07 1997-12-01 Anvendelse av en gp39-antagonist ved fremstilling av et medikament egnet til behandling av ikke-B-lymfocytt-mediert vevsdestruksjon assosiert med multippel sklerose. NO322391B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/481,735 US5833987A (en) 1995-06-07 1995-06-07 Treatment of T cell mediated autoimmune disorders
PCT/US1996/009137 WO1996040246A1 (en) 1995-06-07 1996-06-06 Treatment of t cell mediated autoimmune disorders

Publications (3)

Publication Number Publication Date
NO975520D0 true NO975520D0 (no) 1997-12-01
NO975520L NO975520L (no) 1998-02-06
NO322391B1 NO322391B1 (no) 2006-10-02

Family

ID=23913182

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19975520A NO322391B1 (no) 1995-06-07 1997-12-01 Anvendelse av en gp39-antagonist ved fremstilling av et medikament egnet til behandling av ikke-B-lymfocytt-mediert vevsdestruksjon assosiert med multippel sklerose.
NO20045460A NO20045460L (no) 1995-06-07 2004-12-15 Behandling av T-cellemedierte autoimmune forstyrrelser

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20045460A NO20045460L (no) 1995-06-07 2004-12-15 Behandling av T-cellemedierte autoimmune forstyrrelser

Country Status (17)

Country Link
US (4) US5833987A (no)
EP (2) EP0831906B1 (no)
JP (1) JPH11507058A (no)
KR (1) KR100493482B1 (no)
CN (2) CN1827168A (no)
AT (1) ATE214944T1 (no)
AU (1) AU705623B2 (no)
CA (1) CA2223303A1 (no)
DE (1) DE69620174T2 (no)
DK (1) DK0831906T3 (no)
ES (1) ES2177791T3 (no)
HU (1) HUP9900857A3 (no)
NO (2) NO322391B1 (no)
NZ (1) NZ311276A (no)
PT (1) PT831906E (no)
WO (1) WO1996040246A1 (no)
ZA (1) ZA964851B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
TR199902192T2 (xx) * 1997-01-10 1999-12-21 Biogen,Inc Anti-CDL40 bile�iklerinin tedavi ama�l� uygulama y�ntemleri
WO1999000143A1 (en) * 1997-06-27 1999-01-07 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases
CN100352497C (zh) * 1998-04-03 2007-12-05 达特茅斯学院理事 应用特异性结合cd40cr(cd40 配体)的抗体抑制体液免疫
US20030077667A1 (en) * 1999-06-01 2003-04-24 Jun Tan Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
US6787318B1 (en) * 1999-06-01 2004-09-07 Roskamp Research Institute, Llc Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US20070160615A1 (en) * 1999-06-01 2007-07-12 Jun Tan Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of Alzheimer's disease
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US20020009444A1 (en) * 2000-04-25 2002-01-24 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
US6797263B2 (en) 2000-05-12 2004-09-28 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
WO2001094586A2 (en) * 2000-06-06 2001-12-13 Idec Pharmaceuticals Corporation Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
ATE328906T1 (de) * 2002-06-28 2006-06-15 Domantis Ltd Dual-specifische liganden mit erhöhter halbwertszeit
US20040146949A1 (en) * 2002-10-25 2004-07-29 Jun Tan Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
ES2401536T3 (es) * 2007-11-13 2013-04-22 Evec Inc. Anticuerpos monoclonales que se unen a HGM-CSF y composiciones medicinales que los comprenden
EP2229914B1 (en) * 2009-03-20 2018-05-30 Nobel Biocare Services AG System and method for aligning virtual models
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
KR101614739B1 (ko) * 2015-12-01 2016-04-22 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
MA50435A (fr) 2017-05-24 2020-09-02 Als Therapy Development Inst Anticorps anti-ligand anti-cd40 thérapeutiques
WO2019175332A1 (en) 2018-03-14 2019-09-19 Imba - Institut Für Molekulare Biotechnologie Gmbh Bh4 pathway inhibition and use thereof for treating t-cell mediated autoimmune diseases or hypersensitivity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US5571507A (en) * 1992-02-25 1996-11-05 Seragen, Inc. Methods of treating diabetes
US5958403A (en) * 1992-02-28 1999-09-28 Beth Israel Hospital Association Methods and compounds for prevention of graft rejection
WO1994028912A1 (en) * 1993-06-10 1994-12-22 The Regents Of The University Of Michigan Cd28 pathway immunosuppression
EP0721346B1 (en) * 1993-09-02 1998-06-10 Trustees of Dartmouth College Methods for inducing antigen-specific t cell tolerance
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders

Also Published As

Publication number Publication date
KR19990022273A (ko) 1999-03-25
US20040197327A1 (en) 2004-10-07
AU6255996A (en) 1996-12-30
CN1192156A (zh) 1998-09-02
CN1827168A (zh) 2006-09-06
EP0831906B1 (en) 2002-03-27
US5833987A (en) 1998-11-10
EP0831906A1 (en) 1998-04-01
ATE214944T1 (de) 2002-04-15
ZA964851B (en) 1997-07-29
HUP9900857A3 (en) 1999-11-29
HUP9900857A2 (hu) 1999-07-28
WO1996040246A1 (en) 1996-12-19
AU705623B2 (en) 1999-05-27
NO322391B1 (no) 2006-10-02
NO975520L (no) 1998-02-06
NZ311276A (en) 1999-11-29
CA2223303A1 (en) 1996-12-19
PT831906E (pt) 2002-09-30
ES2177791T3 (es) 2002-12-16
DE69620174D1 (de) 2002-05-02
EP1161954A1 (en) 2001-12-12
DK0831906T3 (da) 2002-05-21
DE69620174T2 (de) 2002-07-18
US20020009450A1 (en) 2002-01-24
JPH11507058A (ja) 1999-06-22
US6328964B1 (en) 2001-12-11
KR100493482B1 (ko) 2005-08-29
NO20045460L (no) 1998-02-06

Similar Documents

Publication Publication Date Title
NO975520L (no) Behandling av T-celle-medierte autoimmune forstyrrelser
AU2002360436A1 (en) 2-aryl pyrrologpyrimidines for a1 and a3 receptors
ATE524176T1 (de) Valsartan tablette
HK1042485B (zh) 促進由ampa受體介導的突觸反應的藥物
CA2260145A1 (en) Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
ZA201001595B (en) Methods of modulating cd200 receptors
WO2000012623A3 (en) Use of 5-th receptor antagonists for the treatment of parkinson's disease
AU9064991A (en) Use of angiotensin ii receptor antagonists in the treatment of diabetic retinopathy
NO944781D0 (no) 2,5-diokso-2,5-dihydro-1H-benz(b)azepiner som NMDA-reseptor-antagonister
ES2159362T3 (es) Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
AU6682298A (en) Use of r-nsaid's for the prevention of alzheimer's disease
NZ502495A (en) Use of a specific antagonist of 5HT2 receptor antagonist for the preparation of medicines useful in the treatment of sleep apnoea syndrome
NO932391D0 (no) Angiotensin-ii reseptorantagonister for behandling av hjerterytmeforstyrrelser
DE3879535D1 (no)
HU9202990D0 (en) A new application of quisqualate receptor antagonists
ITRM930488A0 (it) Composizione detergente per la cura del corpo.
MD970254A (en) Use of melatonine for treatment of patients having a medicamental dependence
WO1998003178A3 (en) Pharmaceutical compositions containing p2y purinergic receptor antagonists
NO953892D0 (no) Imidazolokinoksalinon-derivater som EAA-antagonister
PT942729E (pt) Utilizacao de antagonistas de receptores nk-1 para tratamento de doencas do stresse
MX9710002A (es) Nuevo uso medico.
EP0872239A3 (en) Use of olanzapine for the manufacture of a medicament for the treatment of cerebral focal ischemia
AU4250697A (en) Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection
IT1280968B1 (it) Dispositivo per la pulizia dei laccioli del divisore di un'apparecchiatura di carderia.